Auris Medical Holding Ltd. (NASDAQ: EARS) plunged almost -26.77% at $4.21 in post-market hours, returning some of what it enormously attained yesterday after the news
The Bermuda-based clinical-stage firm reports strong results from its drug-free nasal spray AM-301. The nasal spray results show potential for AM-301 to alleviatethe risk of
At Stocktstelegraph.com, we are committed to helping investors make smart and profitable decisions. Our goal is to make investing easier and more accessible to everyone. We strive to provide the best and most reliable market information, news and analysis to ensure that our readers can make informed decisions.